• Publications
  • Influence
Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American
DESCRIPTION This guideline is an official statement of the American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), and European RespiratoryExpand
  • 786
  • 37
Lebrikizumab treatment in adults with asthma.
BACKGROUND Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in theExpand
  • 876
  • 25
Anxiety and depression in COPD: current understanding, unanswered questions, and research needs.
BACKGROUND Approximately 60 million people in the United States live with one of four chronic conditions: heart disease, diabetes, chronic respiratory disease, and major depression. Anxiety andExpand
  • 161
  • 21
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
RATIONALE For many patients with asthma, allergic airway inflammation is primarily a Th2-weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic distinctions existExpand
  • 554
  • 20
The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD
Study objectives: To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled long-acting β 2 -agonist salmeterol (SM), when administered together inExpand
  • 289
  • 13
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
BACKGROUND Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to haveExpand
  • 337
  • 12
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
BACKGROUND Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β(2) agonist is more protective than a once-daily longacting β(2) agonist alone againstExpand
  • 269
  • 11
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort.
RATIONALE Depression is prevalent in patients with chronic obstructive pulmonary disease (COPD); however, its etiology and relationship to the clinical features of COPD are not well understood. Expand
  • 217
  • 10
Asthma in the elderly: Current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop
Asthma in the elderly is underdiagnosed and undertreated, and there is a paucity of knowledge on the subject. The National Institute on Aging convened this workshop to identify what is known andExpand
  • 196
  • 10
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
Introduction In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised,Expand
  • 257
  • 8